The present disclosure relates to a composition containing ginseng fruit extract. The present disclosure also relates to a composition for relieving premenstrual syndrome and menstrual pain, which contains ginseng fruit extract. The composition according to the present disclosure exhibits an effect of relieving or improving the symptoms of premenstrual syndrome and thus can be used as a pharmaceutical composition or a food composition.

The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO.sub.2, amino, COOH, COOCH.sub.3, OH, N.sub.3, or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O, Bn- optionally substituted, or Ph- optionally substituted.

##STR00001##

Disclosed are compounds having the formula:

##STR00001## wherein X, Y, Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, R.sup.5, R.sup.A, m, A. L, and B are as defined herein, and methods of making and using the same.

The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).

The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-IL-6 and/or anti-CD 126 synthetic antibody. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.

The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

The present invention provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analog or derivative thereof and (ii) a penetration enhancer, and optionally including tannic acid, or an analog or derivative thereof. The present invention also provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analog or derivative thereof, and (ii) tannic acid, or an analog or derivative thereof, optionally including a penetration enhancer. Also provided are kits and methods of prophylactic or therapeutic treatment of inflammatory and/or degenerative conditions using the combination of active ingredients as herein described.

Compounds of Formula I: ##STR00001##
or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.c, R.sup.d, X, Y, B, and Ring C are as defined herein, and wherein the YB moiety and the NHC(X)NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.